Key result
Telmisartan significantly lowered home systolic and diastolic blood pressure and improved insulin resistance in hypertensive patients, without correlation between the changes.
Why the study?
Does switching to telmisartan improve home blood pressure and insulin resistance in hypertensive patients previously treated with another ARB?
Cohort (n=27)
No
Does switching to telmisartan improve home blood pressure and insulin resistance in hypertensive patients previously treated with another ARB?
Switching from another ARB to telmisartan improves both home blood pressure and insulin resistance in hypertensive patients, with these effects appearing to be independent of each other.
May support telmisartan switch in ARB-treated hypertensives; hypothesis-generating for independent effects, pending RCTs.
Telmisartan is an angiotensin type 1 receptor blocker (ARB), which also partially activates liganding peroxisome proliferator-activated receptor gamma. However, the relationship between the effects of telmisartan on hemodynamics and metabolism has not sufficiently been elucidated in clinical settings. We examined the long-term effects of telmisartan on hemodynamics including home blood pressure (BP) and on insulin resistance representing as homeostasis model assessment (HOMA-R). Twenty-seven hypertensive patients were consecutively enrolled at our outpatient department. At entry, all of the participants were previously prescribed another ARB for more than 3 months and then the former ARB were replaced by telmisartan. Hemodynamic and metabolic parameters were measured before treatment and at points 1 and 3 months after treatment with telmisartan. Telmisartan significantly lowered home systolic blood pressure (SBP) and diastolic blood pressure (DBP) (DBP) and improved HOMA-R during the treatment period. However, the changes in home SBP and DBP were not correlated with that of HOMA-R. In conclusion, telmisartan lowers home BP and improves insulin resistance without correlation between their changes.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (2011) conducted a cohort in Hypertension (n=27). Telmisartan vs. Baseline (previous ARB therapy) was evaluated on Home blood pressure (SBP and DBP) and insulin resistance (HOMA-R). Telmisartan significantly lowered home systolic and diastolic blood pressure and improved insulin resistance in hypertensive patients, without correlation between the changes.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: